Location of Repository

Combination Drug Delivery Approaches in Metastatic Breast Cancer

By Jun H. Lee and Anjan Nan


Disseminated metastatic breast cancer needs aggressive treatment due to its reduced response to anticancer treatment and hence low survival and quality of life. Although in theory a combination drug therapy has advantages over single-agent therapy, no appreciable survival enhancement is generally reported whereas increased toxicity is frequently seen in combination treatment especially in chemotherapy. Currently used combination treatments in metastatic breast cancer will be discussed with their challenges leading to the introduction of novel combination anticancer drug delivery systems that aim to overcome these challenges. Widely studied drug delivery systems such as liposomes, dendrimers, polymeric nanoparticles, and water-soluble polymers can concurrently carry multiple anticancer drugs in one platform. These carriers can provide improved target specificity achieved by passive and/or active targeting mechanisms

Topics: Review Article
Publisher: Hindawi Publishing Corporation
OAI identifier: oai:pubmedcentral.nih.gov:3350970
Provided by: PubMed Central
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • http://www.pubmedcentral.nih.g... (external link)
  • Suggested articles



    1. (2005). 6-Mercaptopurine and daunorubicin double drug liposomes– preparation, drug-drug interaction and characterization,”
    2. (2009). A phase i and pharmacokinetic study of paclitaxel poliglumex and cisplatin in patients with advanced solid tumors,”
    3. (1991). A prospective randomized trial comparing epirubicin monochemotherapy to two fluorouracil, cyclophosphamide, and epirubicin regimens differing in epirubicin dose in advanced breast cancer patients,”
    4. (1995). Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: the results of 20 years of follow-up,”
    5. (1985). Biological effects of soluble synthetic polymers asdrugcarriers,”CriticalReviewsinTherapeuticDrugCarrier Systems,
    6. (2003). C o b l e i g h ,V .K .L a n g m u i r ,G .W .S l e d g ee ta l . ,“ AP h a s e I/IIdose-escalationtrialofbevacizumabinpreviouslytreated metastatic breast cancer,” Seminars in Oncology,
    7. (2007). C.A.Hudis,“Trastuzumab—mechanismofactionandusein clinical practice,” New England
    8. (2008). Calderillo-Ruiz et al., “Gemcitabine plus paclitaxel versus paclitaxel monotherapy in patients with metastatic breast cancer and prior anthracycline treatment,”
    9. (2010). Cancer statistics,
    10. (2007). Capecitabine and trastuzumab in heavily pretreated metastatic breast cancer,”
    11. (2007). Cardiac safety and antitumoral activity of a new nitric oxide derivative of pegylated epirubicininmice,”
    12. Characterization of PEGylated nanoliposomes co-remotely loaded with topotecan and vincristine: relating structure and pharmacokinetics to therapeutic efficacy,” Journal of Controlled Release .
    13. (2010). Co-delivery of as-miR21 and 5-FU by poly(amidoamine) dendrimer attenuates h u m a ng l i o m ac e l lg r o w t hi nv i t r o ,
    14. (2006). Co-delivery of drugs and DNA from cationic core-shell nanoparticles self-assembled from a biodegradable copolymer,”
    15. (2010). Co-delivery of siRNA and paclitaxel into cancer cells by biodegradable cationic micelles based on PDMAEMA-PCL-PDMAEMA triblock copolymers,”
    16. (2001). Combination chemotherapy and photodynamic therapy of targetable N-(2-hydroxypropyl) methacrylamide copolymer-doxorubicin/mesochlorin e6-OV-TL 16 antibody immunoconjugates,”
    17. (1998). Combination chemotherapy versus single-agent therapy as first- and second-line treatment in metastatic breast cancer: a prospective randomized trial,”
    18. (1998). Controlling liposome blood clearance by surface-grafted polymers,”
    19. (2009). Current combination chemotherapy regimens for metastatic breast cancer,”
    20. (1998). Cytotoxic and hormonal treatment for metastatic breast cancer: a systematic review of published randomized trials involving 31,510 women,”
    21. (2007). Dendrimers as multi-purpose nanodevices for oncology drug delivery and diagnostic imaging,”
    22. (2011). Dendritic poly(ethylene glycol) bearing paclitaxel and alendronate for targeting bone neoplasms,”
    23. (2010). Development of PLGA nanoparticles simultaneously loaded with vincristine and verapamil for treatment of hepatocellular carcinoma,”
    24. (2001). Dose-intensive epirubicin-based chemotherapy is superior to an intensive intravenous cyclophosphamide, methotrexate, and fluorouracil regimen in metastatic breast cancer: a randomized multinational study,”
    25. (2001). Doxorubicin and paclitaxel versus fluorouracil, doxorubicin, and cyclophosphamide as first-line therapy for women with metastatic breast cancer: final results of a randomized phase III multicenter trial,”
    26. (2009). Drug ratio-dependent antitumor activity of irinotecan and cisplatin combinations in vitro and in vivo,”
    27. (2009). efficacy of CPX-1 liposome injection in patients with advanced solid tumors,”
    28. (2000). Efficacy of the chemotherapeutic action of HPMA copolymer-bound doxorubicin in a solid tumor model of ovarian carcinoma,”
    29. (2011). Enhanced anti-tumor effi-cacy by co-delivery of doxorubicin and paclitaxel with amphiphilic methoxy PEG-PLGA copolymer nanoparticles,”
    30. (2004). Enhancement of chemotherapeutic response of tumor cells by a heme oxygenase inhibitor, pegylated zinc protoporphyrin,”
    31. (2006). erez-Tom´ as, “Multidrug resistance: retrospect and prospects in anti-cancer drug treatment,”
    32. (2008). Evaluation of tumor response, disease control, progressionfree survival, and time to progression as potential surrogateJournal of Drug Delivery 15 end points in metastatic breast cancer,”
    33. (2009). F.GrecoandM.J.Vicent,“Combinationtherapy:opportunitiesandchallengesforpolymer-drugconjugatesasanticancer nanomedicines,” Advanced Drug Delivery Reviews,
    34. (1995). Health-related quality of life as a treatment endpoint in metastatic breast cancer,” The Canadian journal of oncology,
    35. (2005). HPMA copolymer-aminoglutethimide conjugates inhibit aromatase in MCF-7 cell lines,”
    36. (2009). HPMA-based polymer conjugates with drug combination,”
    37. (2011). In vitro evaluation of HER2 targeted N-(2-hydroxypropyl)methacrylamide (HPMA) copolymer conjugates in combination treatment with tyrosine kinase inhibitor (PKI-166),”
    38. (2008). Incorporation of antiangiogenictherapiesinthetreatmentofmetastaticbreast cancer,”
    39. (1993). Influence of treatment schedule on toxicity and efficacy of cyclophosphamide, epirubicin, and fluorouracil in metastatic breast cancer: a randomized trial comparing weekly and every-4-week administration,”
    40. (2011). Iniparib plus chemotherapy in metastatic triple-negative breast cancer,”
    41. (2002). Internalizing antibodies are necessary for improved therapeutic efficacy of antibodytargeted liposomal drugs,”
    42. (2010). International guidelines for management of metastatic breast cancer: can metastatic breast cancer be cured?”
    43. (2008). Intra and inter-molecular interactions dictate the aggregation state of irinotecan co-encapsulated with floxuridine inside liposomes,”PharmaceuticalResearch,vol.25,no.7,pp.1702– 1713,
    44. (2007). Investigating the mechanism of enhanced cytotoxicity of HPMA copolymerDox-AGM in breast cancer cells,”
    45. (2008). Jumping higher: Is it still possible?
    46. (2011). Kolitz et al., “First-in-man study of CPX-351: a liposomal carrier containing cytarabine and daunorubicin in a fixed 5:1 molar ratio for the treatment of relapsed and refractory acute myeloid leukemia,”
    47. (2010). Kopeˇ ckov´ a, “HPMA copolymers: origins, early developments, present, and future,”
    48. (1996). Lambin,“Productionandpropertiesofmonoclonalantibodies against human
    49. (2010). Lapatinib plus capecitabine in women with HER-2-positive advanced breast cancer: final survival analysis of a phase III randomized trial,”
    50. (2007). Lapatinib-associated toxicity and practical management recommendations,”
    51. (2006). Lapatinib: current status and future directions in breast cancer,”
    52. Lessons from phase III clinical trials on anti-VEGF therapy for cancer,”
    53. (2011). Liposome formulation of co-encapsulated vincristine and quercetin enhanced antitumor activity in a trastuzumab-insensitive breast tumor xenograft model,”
    54. (1996). Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer,”
    55. (1997). Mitoxantrone, 5-fluorouracil and highdose leucovorin (NFL) in the treatment of metastatic breast cancer: randomized comparison to cyclophosphamide, methotrexate and 5-fluorouracil (CMF) and attempts to improve efficacy by adding paclitaxel,”
    56. (2007). Mixed polymeric micelles for combination cancer chemotherapy through the concurrent delivery of multiple chemotherapeutic agents,”
    57. (2011). Multi-drug delivery to tumor cells via micellar nanocarriers,”
    58. (2009). Multi-drug loaded polymeric micelles for simultaneous delivery of poorly soluble anticancer drugs,”
    59. Multifunctional nanoparticles delivering small interfering RNA and doxorubicin overcome drug resistance in cancer,”
    60. (2010). Multifunctional tumor-targeted polymerpeptide-drug delivery system for treatment of primary and metastatic cancers,”
    61. (2006). Nitric oxide modulates proapoptotic and antiapoptotic properties of chemotherapy agents: the case of NO-pegylated epirubicin,”
    62. (2009). Non-pegylated liposomal doxorubicin in combination with cyclophosphamideordocetaxelasfirst-linetherapyinmetastaticbreast cancer: a retrospective analysis,” Tumori,v o l .9 5 ,n o .4 ,p p .
    63. (2007). Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer,”
    64. (2006). Paclitaxel Poliglumex (PPX-Xyotax) and concurrent radiation for esophageal and gastric cancer: a phase I study,”
    65. (2000). Palliative effect of chemotherapy: objective tumor response is associated with symptom improvement
    66. (2011). Pharmacokinetics and biodistribution of lonidamine/paclitaxel loaded, EGFRtargeted nanoparticles in an orthotopic animal model of multi-drug resistant breast cancer,”
    67. (2008). Phase I dose escalation and pharmacokinetic study of lapatinib in combination with trastuzumab in patients with advanced ErbB2-positive breast cancer,”
    68. (2008). Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane,”
    69. (2007). Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva lung cancer investigation trial,”
    70. (2008). Phase III, doubleblind, randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as first-line treatment for metastaticbreastcancer,”JournalofClinicalOncology,vol.26,
    71. (1973). Poly[N-(2-hydroxypropyl) methacrylamide]-I. Radical polymerization and copolymerization,”
    72. (2006). Polymer conjugates as anticancer nanomedicines,”
    73. (1994). Polymer conjugates. Pharmacokinetic considerations for design and development,”
    74. (2011). Polymer-drug conjugates as nano-sized medicines,”
    75. (2009). Polymer-drug conjugates for combination anticancer therapy: investigating the mechanism of action,”
    76. (2005). Polymer-drug conjugates: towards a novel approach for the treatment of endrocine-related cancer,”
    77. (2010). Polymercaged nanobins for synergistic cisplatin-doxorubicin combination chemotherapy,”
    78. (2008). Primaryresistancetocetuximab therapyinEGFRFISH-positive colorectal cancer patients,”
    79. (2006). Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2—overexpressing metastatic breast cancer,”
    80. (2010). Randomized study of Lapatinib alone or in combination with trastuzumab
    81. (1986). randomizedtrialinpostmenopausalpatientswithadvanced breast cancer comparing endocrine and cytotoxic therapy given sequentially or in combination. The Australian and New Zealand Breast Cancer Trials Group,
    82. (2005). Recent advances with liposomes as pharmaceutical carriers,”
    83. (2007). Reversal of multidrug resistance by transferrin-conjugated liposomes co-encapsulating doxorubicin and verapamil,”
    84. (2000). Reversion of multidrug resistance by coencapsulationofdoxorubicinandcyclosporinAinpolyalkylcyanoacrylate nanoparticles,”
    85. (2009). S.Chan,G.Romieu,J.Huober etal.,“PhaseIIIstudyofgemcitabineplusdocetaxelcomparedwithcapecitabineplusdocetaxel for anthracycline-pretreated patients with metastatic breast cancer,”
    86. (2005). S.Sengupta,D.Eavarone,I.Capilaetal.,“Temporaltargeting of tumour cells and neovasculature with a nanoscale delivery system,”
    87. (2002). Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results,”
    88. (2010). Survival benefits from lapatinib therapy in women with HER2-overexpressing breast cancer: a systematic review,” Anti-Cancer Drugs,
    89. (2000). Systematic reviews of chemotherapy and endocrine therapy in metastatic breast cancer,”
    90. (1992). Systemic therapy of advanced breast cancer,”
    91. (2008). T e k a d e ,T .D u t t a ,A .T y a g i ,A .C .B h a r t i
    92. (2007). T h o m a s ,H .L .G o m e z ,R .K .L ie ta l . ,“ I x a b e p i l o n ep l u s capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment,”
    93. (2009). T.Lammers,V.Subr,K.Ulbrichetal.,“Simultaneousdelivery of doxorubicin and gemcitabine to tumors in vivo using prototypicpolymericdrugcarriers,”Biomaterials,vol.30,no. 20,
    94. (2006). Tardi et al., “Ratiometric dosing of anticancer drug combinations: controlling drug ratios after systemic administration regulates therapeutic activity in tumor-bearing mice,”
    95. (2011). Targeted chemoimmunotherapy using drug-loaded aptamer-dendrimer bioconjugates,”
    96. (2012). Targeted delivery of a combination therapy consisting of combretastatin A4 and low-doseJournal of Drug Delivery 17 doxorubicin against tumor neovasculature,”
    97. (2009). Targeted intracellular codelivery of chemotherapeutics and nucleic acid with a welldefined dendrimer-based nanoglobular carrier,”
    98. (2007). Targeted nanoparticlebaseddrugdeliveryanddiagnosis,”JournalofDrugTargeting,
    99. (2008). Targeted therapy for cancer using PARP inhibitors,”
    100. (2009). Targeting angiogenesisdependent calcified neoplasms using combined polymer therapeutics,”
    101. (2009). Targeting bone metastases with a bispecific anticancer and antiangiogenic polymer-alendronate-taxane conjugate,”
    102. (2005). Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy,”
    103. (2005). Taxanes with anthracyclines as first-line chemotherapy for metastatic breast carcinoma: pooled analysis of 2805 patients,”
    104. (2010). The emerging role of PARP inhibitors in the treatment of epithelial ovarian cancer,”
    105. (2011). Therapeutic potential of poly(ADP-ribose) polymerase inhibitor AG014699 in human cancers with mutated or methylated BRCA1 or BRCA2,”
    106. (2010). Treatment of breast cancer,”
    107. (2009). Treatment options for breast cancer resistant to anthracycline and taxane,”
    108. (2011). Triple-negative breast cancer: an unmet medical need,”
    109. (2000). Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review,”
    110. (2010). Tyrosine kinase inhibitors and multidrug resistance proteins: interactions and biological consequences,”

    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.